@article {7424,
	title = {Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)},
	journal = {Leukemia and Lymphoma},
	volume = {57},
	year = {2016},
	note = {Cited By :1Export Date: 21 February 2017},
	month = {2016},
	pages = {2839 - 2847},
	abstract = {Relapsed/refractory multiple myeloma (RRMM) patients have poor overall survival (OS). Pomalidomide plus low-dose dexamethasone (POM + LoDEX) significantly extends OS in RRMM vs. high-dose dexamethasone. Survival of patients with stable disease (SD) was compared to patients with progressive disease (PD) or >= partial response (>=PR) at cycles (C) 3, 5, and 7. Among 302 patients randomized to POM + LoDEX, at C3 19.2\% achieved >= PR, 38.4\% SD, and 14.6\% PD. Patients with SD at C3 (17.4\%) and C5 (13.6\%) showed improved responses at C7. Median OS from randomization by response at C3 was 22.4 months for >= PR (n = 58, HR 0.66; 95\% CI 0.40{\textendash}1.08, p = 0.0976 vs. SD), 16.2 months for SD (n = 116), and 6.3 months for PD (n = 44, HR 3.43; 95\% CI 2.23{\textendash}5.27, p < 0.0001 vs. SD). Similar patterns were observed for C5 and C7. Results show that POM + LoDEX should be a standard treatment after lenalidomide and bortezomib, including in SD patients. {\^A}{\textcopyright} 2016 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.},
	keywords = {MM-003, multiple myeloma, pomalidomide},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84966930023\&doi=10.1080\%2f10428194.2016.1180685\&partnerID=40\&md5=1977c141c833453201ad66eed8d97517},
	author = {Moreau, P. and Weisel, K.C. and Song, K.W. and Gibson, C.J. and Saunders, O. and Sternas, L.A. and Hong, K. and Zaki, M.H. and Dimopoulos, M.A.}
}
